Status:
UNKNOWN
Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome
Lead Sponsor:
Tehran University of Medical Sciences
Conditions:
Bartter Syndrome
Eligibility:
All Genders
1-10 years
Brief Summary
In this prospective controlled cross over clinical trial, the investigators aim to evaluate the efficacy and safety of acetazolamide for the management of metabolic alkalosis in children with Bartter ...
Detailed Description
Bartter syndrome is a hereditary salt-loosing tubulopathy caused by several gene mutations encoding the sodium reabsorption in the thick ascending limb of loop of Henle, with poor response to treatmen...
Eligibility Criteria
Inclusion
- Hypokalemia
- metabolic alkalosis
- normal blood pressure
- random urine chloride \>20 milliequivalent per liter (mEq/L)
- Elevated serum aldosterone and renin levels
Exclusion
- Hypertension
- History of emesis
- Prior use of laxatives
- Cystic fibrosis ofpancrease
Key Trial Info
Start Date :
January 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2019
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03847571
Start Date
January 10 2019
End Date
December 30 2019
Last Update
February 20 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Fateme Ghane Sharbaf
Mashhad, Iran
2
Semnan University of Medical Sciences
Semnan, Iran, 011000
3
Banafshe Dormansh
Tehran, Iran
4
Simin Sadeghi
Zahedan, Iran